The impact of nirsevimab prophylaxis on RSV hospitalizations: a real-world cost-benefit analysis in Tuscany, Italy

The impact of nirsevimab prophylaxis on RSV hospitalizations: a real-world cost-benefit analysis in Tuscany, Italy

BackgroundRespiratory Syncytial Virus (RSV) is the leading cause of hospitalizations in infants. The approval of nirsevimab, a long-acting monoclonal antibody, has extended the potential for RSV prophylaxis to all infants. This study assesses the cost–benefit of various Nirsevimab prophylaxis strate...

Full description

Saved in:
Bibliographic Details
Main Authors: Vieri Lastrucci, Martina Pacifici, Giorgia Alderotti, Monia Puglia, Elettra Berti, Federica Barbati, Lorenzo Lodi, Silvia Boscia, Francesco Nieddu, Giuseppe Indolfi, Diego Peroni, Marco Martini, Chiara Azzari, Fabio Voller, Maria Moriondo, Silvia Ricci
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Public Health
Subjects:
respiratory syncytial virus (RSV)
immunization
prevention
nirsevimab
hospitalizations
cost–benefit analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fpubh.2025.1604331/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items